Marshall Wace, LLP Morpho Sys Ag Transaction History

Marshall Wace, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.6 - $18.18 $525,675 - $1.11 Million	-61,125 Reduced 18.75%	264,961 $4.81 Million
Q4 2023 Feb 14, 2024	BUY	$4.55 - $9.9 $743,529 - $1.62 Million	163,413 Added 100.45%	326,086 $3.23 Million
Q3 2023 Nov 14, 2023	SELL	$6.72 - $8.6 $227,814 - $291,548	-33,901 Reduced 17.25%	162,673 $1.09 Million
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $776,467 - $1.52 Million	196,574 New	196,574 $1.47 Million
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $66,319 - $109,929	-11,298 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$9.08 - $12.45 $192,450 - $263,877	-21,195 Reduced 65.23%	11,298 $107,000
Q3 2021 Nov 15, 2021	BUY	$11.76 - $19.51 $260,495 - $432,166	22,151 Added 214.18%	32,493 $382,000
Q2 2021 Aug 13, 2021	BUY	$18.95 - $23.95 $195,980 - $247,690	10,342 New	10,342 $199,000
Q1 2021 May 17, 2021	SELL	$21.56 - $30.66 $396,337 - $563,622	-18,383 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$24.81 - $30.33 $1.09 Million - $1.33 Million	-43,764 Reduced 70.42%	18,383 $521,000
Q3 2020 Nov 16, 2020	SELL	$30.28 - $35.72 $100,650 - $118,733	-3,324 Reduced 5.08%	62,147 $1.95 Million
Q2 2020 Aug 13, 2020	BUY	$24.08 - $33.35 $1.58 Million - $2.18 Million	65,471 New	65,471 $2.07 Million
Q2 2019 Aug 14, 2019	SELL	$23.24 - $26.76 $91,565 - $105,434	-3,940 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$22.55 - $29.84 $542,688 - $718,129	-24,066 Reduced 85.93%	3,940 $90,000
Q4 2018 Feb 14, 2019	BUY	$21.96 - $31.02 $615,011 - $868,746	28,006 New	28,006 $707,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.